Oncogenic JAK2 V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms
Alessandro Prestipino,Alica J. Emhardt,Konrad Aumann,David O’Sullivan, Sivahari Prasad Gorantla,Sandra Duquesne,Wolfgang Melchinger,Lukas Braun,Slavica Vučković,Melanie Boerries,Hauke Busch,Sebastian Halbach,Sandra Pennisi,Teresa Poggio,Petya Apostolova,Pia Veratti,Michael Hettich,Gabriele Niedermann,Mark Bartholomä,Khalid Shoumariyeh,Jonas S. Jutzi,Julius Wehrle,Christine Dierks,Heiko Becker,Annette Schmitt-Gräeff,Marie Follo,Dietmar Pfeifer,Jan Rohr,Sebastian Fuchs,Stephan Ehl,Frederike A. Hartl,Susana Minguet,Cornelius Miething,Florian H. Heidel,Nicolaus Kröger,Ioanna Triviai,Tilman Brummer,Jürgen Finke,Anna Lena Illert,Eliana Ruggiero,Chiara Bonini,Justus Duyster,Heike L. Pahl,Steven Lane,Geoffrey R. Hill,Bruce R. Blazar,Nikolas von Bubnoff,Erika L. Pearce,Robert Zeiser Science Translational Medicine(2018)
摘要
Oncogenic JAK mutation sensitizes myeloproliferative neoplasms to immune checkpoint inhibition.
更多查看译文
关键词
oncogenic jak2,immune escape,neoplasms
AI 理解论文
溯源树
样例